keyword
MENU ▼
Read by QxMD icon Read
search

Bicalutamide

keyword
https://www.readbyqxmd.com/read/29658567/hepacam-inhibits-the-malignant-behavior-of-castration-resistant-prostate-cancer-cells-by-downregulating-notch-signaling-and-pf-3084014-a-%C3%AE-secretase-inhibitor-partly-reverses-the-resistance-of-refractory-prostate-cancer-to-docetaxel-and-enzalutamide-in-vitro
#1
Zhongbo Du, Luo Li, Wei Sun, Xiao Wang, Yao Zhang, Zhixiong Chen, Mengjuan Yuan, Zhen Quan, Nanjing Liu, Yanni Hao, Ting Li, Jinhua Wang, Chunli Luo, Xiaohou Wu
Castration-resistant prostate cancer (CRPC) continues to be a major challenge in the treatment of prostate cancer (PCa). The expression of hepatocyte cell adhesion molecule (HepaCAM), a novel tumor suppressor, is frequently downregulated or lost in PCa. Overactivated Notch signaling is involved in the development and progression of PCa, including CRPC. In this study, we found that the activities of Notch signaling were elevated, while HepaCAM expression was decreased in CRPC tissues compared with matched primary prostate cancer (PPC) tissues...
April 12, 2018: International Journal of Oncology
https://www.readbyqxmd.com/read/29642934/correlation-of-gene-expression-and-associated-mutation-profiles-of-apobec3a-apobec3b-rev1-ung-and-fhit-with-chemosensitivity-of-cancer-cell-lines-to-drug-treatment
#2
Suleyman Vural, Richard Simon, Julia Krushkal
BACKGROUND: The APOBEC gene family of cytidine deaminases plays important roles in DNA repair and mRNA editing. In many cancers, APOBEC3B increases the mutation load, generating clusters of closely spaced, single-strand-specific DNA substitutions with a characteristic hypermutation signature. Some studies also suggested a possible involvement of APOBEC3A, REV1, UNG, and FHIT in molecular processes affecting APOBEC mutagenesis. It is important to understand how mutagenic processes linked to the activity of these genes may affect sensitivity of cancer cells to treatment...
April 11, 2018: Human Genomics
https://www.readbyqxmd.com/read/29624463/phase-iii-intergroup-trial-of-adjuvant-androgen-deprivation-with-or-without-mitoxantrone-plus-prednisone-in-patients-with-high-risk-prostate-cancer-after-radical-prostatectomy-swog-s9921
#3
Maha Hussain, Catherine M Tangen, Ian M Thompson, Gregory P Swanson, David P Wood, Wael Sakr, Nancy A Dawson, Naomi B Haas, Thomas W Flaig, Tanya B Dorff, Daniel W Lin, E David Crawford, David I Quinn, Nicholas J Vogelzang, L Michael Glode
Purpose Patients with high-risk prostate cancer after radical prostatectomy are at risk for death. Adjuvant androgen-deprivation therapy (ADT) may reduce this risk. We hypothesized that the addition of mitoxantrone and prednisone (MP) to adjuvant ADT could reduce mortality compared with adjuvant ADT alone. Methods Eligible patients had cT1-3N0 prostate cancer with one or more high-risk factors after radical prostatectomy (Gleason score [GS] ≥ 8; pT3b, pT4, or pN+ disease; GS 7 and positive margins; or preoperative prostate-specific antigen [PSA] > 15 ng/mL, biopsy GS score > 7, or PSA > 10 ng/mL plus biopsy GS > 6...
April 6, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29600433/estrogen-therapy-in-patients-with-prostate-cancer-a-contemporary-systematic-review
#4
REVIEW
Leonardo Oliveira Reis, Emerson Luis Zani, Herney Andrés García-Perdomo
PURPOSE: To evaluate the effectiveness and harms of DES in treating prostate cancer compared to other forms of androgen deprivation therapy (orchiectomy, LHRH agonists, and anti-androgens). METHODS: We included clinical trials comparing DES with other forms of ADT (bicalutamide, flutamide, LHRH agonists, or orchiectomy) in PCa treatment. The primary outcomes were overall survival, cancer-specific survival, and progression-free survival, and secondary outcomes were cardiovascular effects...
March 29, 2018: International Urology and Nephrology
https://www.readbyqxmd.com/read/29533281/a-case-of-a-malignant-cutaneous-mixed-tumor-chondroid-syringoma-of-the-scapula-treated-with-staged-margin-controlled-excision
#5
Karan Lal, Travis J Morrell, Michael Cunningham, Patrick OʼDonnell, Nikki A Levin, Kristine M Cornejo
Cutaneous mixed tumor (chondroid syringoma) is the cutaneous counterpart of pleomorphic adenoma of salivary glands, comprised of both epithelial and mesenchymal components. Malignant transformation is exceptionally rare, with only a few cases reported. We report a case of a malignant cutaneous mixed tumor in an 86-year-old white man who presented with a pink indurated plaque on his left scapula. He had a history of nonmelanoma skin cancers, a stage IB malignant melanoma of a lower extremity and Gleason 4 + 3 prostate cancer treated with brachytherapy, external beam irradiation, and bicalutamide...
March 6, 2018: American Journal of Dermatopathology
https://www.readbyqxmd.com/read/29497605/enzalutamide-and-blocking-androgen-receptor-in-advanced-prostate-cancer-lessons-learnt-from-the-history-of-drug-development-of-antiandrogens
#6
REVIEW
Yusuke Ito, Marianne D Sadar
Enzalutamide is a nonsteroidal antiandrogen for the treatment of metastatic castration-resistant prostate cancer (mCRPC) both before and after chemotherapy. Enzalutamide is more effective than its predecessor bicalutamide, which was analyzed in head-to-head studies of patients with CRPC. This family of nonsteroidal antiandrogens is now comprised of four drugs approved by the US Food and Drug Administration with two investigational drugs in clinical trials. Antiandrogens have been employed clinically for more than five decades to provide a rich resource of information...
2018: Research and Reports in Urology
https://www.readbyqxmd.com/read/29481948/enhanced-dissolution-of-solid-dispersions-containing-bicalutamide-subjected-to-mechanical-stress
#7
Joanna Szafraniec, Agata Antosik, Justyna Knapik-Kowalczuk, Krzysztof Chmiel, Mateusz Kurek, Karolina Gawlak, Marian Paluch, Renata Jachowicz
The anticancer drug bicalutamide was co-milled with either Macrogol6000 or Poloxamer407, and the physicochemical parameters that drive the phase transition of binary systems and influence the dissolution modification of bicalutamide were studied. Milled binary systems with reduced particle size were assessed by scanning electron microscopy and laser diffraction measurements. The results of thermal analysis supported by X-ray diffractometry confirmed the reduction of the crystallinity of bicalutamide co-milled with Macrogol6000...
February 23, 2018: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/29449534/trim36-a-novel-androgen-responsive-gene-enhances-anti-androgen-efficacy-against-prostate-cancer-by-inhibiting-mapk-erk-signaling-pathways
#8
Chao Liang, Shangqian Wang, Chao Qin, Meilin Bao, Gong Cheng, Bianjiang Liu, Pengfei Shao, Qiang Lv, Ninghong Song, Lixin Hua, Min Gu, Jie Li, Zengjun Wang
Hormone therapy drugs, such as bicalutamide and enzalutamide, directed against prostate cancer focus on androgen receptor (AR) signaling and are initially effective, but the disease progresses to lethality as resistance to these drugs develops. A method to prolong the drug response time and improve the drug efficacy is still unavailable. TRIM36 was reported as a novel androgen signaling target gene and is upregulated in prostate cancer. In this study, we found that 63.4% (64/95) of PCa in TMA expressed the TRIM36 protein...
February 5, 2018: Cell Death & Disease
https://www.readbyqxmd.com/read/29434990/abiraterone-acetate-withdrawal-syndrome-speculations-on-the-underlying-mechanisms
#9
Tomonori Kato, Akira Komiya, Joji Yuasa, Kanya Kaga, Mayuko Kaga, Satoko Kojima, Yukio Naya, Shigeo Isaka
A 72-year-old man initially presented with lumbar and right chest pain, but was later found out to also have an elevated prostate-specific antigen (PSA) level at 2,000.0 ng/ml. Further evaluation disclosed metastatic prostate cancer involving the bones and lymph nodes. The patient was initially treated with combined androgen blockade (CAB) with leuprolide acetate and bicalutamide. After 6 months of CAB, the patient's PSA level began to rise from the nadir (85.1 ng/ml) to 113.3 ng/ml. Bicalutamide was withdrawn in anticipation of anti-androgen withdrawal syndrome and the PSA level declined temporally...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29388185/the-association-of-a-number-of-risk-factors-with-depression-in-patients-with-prostate-cancer-undergoing-androgen-deprivation-therapy
#10
Chang Hee Kim, Kwang Teack Kim, Jin Kyu Oh, Kyung Jin Chung, Tae Beom Kim, Han Jung, Sang Jin Yoon, Khae Hawn Kim
PURPOSE: To identify factors affecting depressive symptoms in patients undergoing androgen-deprivation therapy (ADT) to treat prostate cancer. MATERIALS AND METHODS: The patients with prostate cancer visiting the psychiatry department without referral because of depressive symptoms while undergoing ADT participated. To assess depressive symptoms, the Beck Depression Inventory (BDI) was used. To identify the risk factors affecting depressive symptoms, univariate regression and multiple linear regression analyses were implemented...
February 1, 2018: Urology Journal
https://www.readbyqxmd.com/read/29383406/use-of-androgen-deprivation-and-salvage-radiation-therapy-for-patients-with-prostate-cancer-and-biochemical-recurrence-after-prostatectomy
#11
Pirus Ghadjar, Daniel M Aebersold, Clemens Albrecht, Dirk Böhmer, Michael Flentje, Ute Ganswindt, Stefan Höcht, Tobias Hölscher, Felix Sedlmayer, Frederik Wenz, Daniel Zips, Thomas Wiegel
AIM: Overview on the use of androgen deprivation therapy (ADT) added to salvage radiation therapy (SRT) for prostate cancer patients with biochemical recurrence after prostatectomy. METHODS: The German Society of Radiation Oncology (DEGRO) expert panel summarized available evidence published between January 2009 and May 2017, and assessed the validity of the information on outcome parameters including overall survival (OS) and treatment-related toxicity. RESULTS: Two randomized controlled trials and nine relevant retrospective analyses were identified...
January 30, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29383141/yap1-regulates-prostate-cancer-stem-cell-like-characteristics-to-promote-castration-resistant-growth
#12
Ning Jiang, Binghu Ke, Kim Hjort-Jensen, Diego Iglesias-Gato, Zhun Wang, Pengcheng Chang, Yang Zhao, Xiaodan Niu, Tao Wu, Bo Peng, Mingdong Jiang, Xiaoshi Li, Zhiqun Shang, Qiang Wang, Chawnshang Chang, Amilcar Flores-Morales, Yuanjie Niu
Castration resistant prostate cancer (CRPC) is a stage of relapse that arises after various forms of androgen ablation therapy (ADT) and causes significant morbidity and mortality. However, the mechanism underlying progression to CRPC remains poorly understood. Here, we report that YAP1, which is negatively regulated by AR, influences prostate cancer (PCa) cell self-renewal and CRPC development. Specifically, we found that AR directly regulates the methylation of YAP1 gene promoter via the formation of a complex with Polycomb group protein EZH2 and DNMT3a...
December 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/29381490/comparison-of-the-effect-of-the-antiandrogen-apalutamide-arn-509-versus-bicalutamide-on-the-androgen-receptor-pathway-in-prostate-cancer-cell-lines
#13
Michael I Koukourakis, Christos Kakouratos, Dimitra Kalamida, Achilleas Mitrakas, Stamatia Pouliliou, Erasmia Xanthopoulou, Evdokia Papadopoulou, Virginia Fasoulaki, Alexandra Giatromanolaki
Apalutamide (ARN-509) is an antiandrogen that binds selectively to androgen receptors (AR) and does not show antagonist-to-agonist switch like bicalutamide. We compared the activity of ARN versus bicalutamide on prostate cancer cell lines. The 22Rv1, PC3, and DU145 cell lines were used to study the effect of ARN and bicalutamide on the expression cytoplasmic/nuclear kinetics of AR, AR-V7 variant, phosphorylated AR, as well as the levels of the AR downstream proteins prostate-specific antigen and TMPRSS2, under exposure to testosterone and/or hypoxia...
January 29, 2018: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29377270/frontal-fibrosing-alopecia-after-antiandrogen-hormonal-therapy-in-a-male-patient
#14
LETTER
A Lobato-Berezo, A March-Rodríguez, G Deza, M Bertolín-Colilla, R M Pujol
No abstract text is available yet for this article.
January 29, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29339807/overexpression-of-%C3%AE-1-6-fucosyltransferase-in-the-development-of-castration-resistant-prostate-cancer-cells
#15
Naseruddin Höti, Shuang Yang, Yingwei Hu, Punit Shah, Michael C Haffner, Hui Zhang
Glycosylation is recognized as one of the most common modifications on proteins. Recent studies have shown that aberrant expression of α (1,6) fucosyltransferase (FUT8), which catalyzes the transfer of fucose from GDP-fucose to core-GlcNAc of the N-linked glycoproteins, modulates cellular behavior that could lead to the development of aggressive prostate cancer. While the relationship between the abnormal expression of FUT8 and glycoprotein fucosylation in different prostate cancer cells has been demonstrated, there is no evidence that shows dysregulated fucosylation might be involved in prostate cancer progression from androgen-dependent to castration-resistant prostate cancer...
April 2018: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/29216878/adaptive-phenotype-drives-resistance-to-androgen-deprivation-therapy-in-prostate-cancer
#16
Nicoletta Ferrari, Ilaria Granata, Matteo Capaia, Marina Piccirillo, Mario Rosario Guarracino, Roberta Venè, Antonella Brizzolara, Andrea Petretto, Elvira Inglese, Martina Morini, Simonetta Astigiano, Adriana Agnese Amaro, Francesco Boccardo, Cecilia Balbi, Paola Barboro
BACKGROUND: Prostate cancer (PCa), the second most common cancer affecting men worldwide, shows a broad spectrum of biological and clinical behaviour representing the epiphenomenon of an extreme heterogeneity. Androgen deprivation therapy is the mainstay of treatment for advanced forms but after few years the majority of patients progress to castration-resistant prostate cancer (CRPC), a lethal form that poses considerable therapeutic challenges. METHODS: Western blotting, immunocytochemistry, invasion and reporter assays, and in vivo studies were performed to characterize androgen resistant sublines phenotype in comparison to the parental cell line LNCaP...
December 8, 2017: Cell Communication and Signaling: CCS
https://www.readbyqxmd.com/read/29214142/molecular-mechanisms-of-enzalutamide-resistance-in-prostate-cancer
#17
REVIEW
Zoran Culig
Purpose of Review: Compensatory mechanisms leading to increased androgen receptor expression and activity after androgen ablation or anti-androgen treatment have been identified in prostate cancer. After hydroxyflutamide and bicalutamide were used in therapy of prostate cancer over many years, novel anti-androgen enzalutamide showed improved clinical activity. However, enzalutamide resistance develops over a certain time period, and molecular mechanisms responsible for this process are heterogeneous...
2017: Current Molecular Biology Reports
https://www.readbyqxmd.com/read/29212868/painful-testicular-metastasis-from-prostate-adenocarcinoma
#18
Karla A Lee, Erik Mayer, Vincent Khoo
A 60-year-old man presented with unilateral testicular pain and urinary frequency. His presenting prostate-specific antigen (PSA) was 100 ng/mL, and a biopsy revealed Gleason 4+4 prostate adenocarcinoma. The significance of his initial PSA was somewhat complicated by possible prostatitis and early initiation of bicalutamide. PSA rose on two occasions prior to radiotherapy but coincided with a flare of testicular pain on one of these. Whole-body staging diffusion-weighted MRI scan was negative. He was treated with 3 years of androgen deprivation therapy (ADT) and radical radiotherapy...
December 5, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/29211888/combined-oral-contraception-and-bicalutamide-in-polycystic-ovary-syndrome-and-severe-hirsutism-a-double-blind-randomized-controlled-trial
#19
Costanzo Moretti, Laura Guccione, Paola Di Giacinto, Ilaria Simonelli, Caterina Exacoustos, Vincenzo Toscano, Cecilia Motta, Vincenzo De Leo, Felice Petraglia, Andrea Lenzi
Context: Hirsutism often occurs in women with polycystic ovary syndrome (PCOS). The efficacy of oral contraceptive pill (OCP) plus antiandrogens in the treatment of its severe expression is controversial due to the lack of randomized, double-blind, long-term studies. Objective: The primary outcome was the reduction of hirsutism in PCOS women objectively measured by videodermoscopy on the androgen-sensitive skin areas assessed by the modified Ferriman and Gallwey (mF&G) total score, after 12 months of therapy with OCP + bicalutamide (BC) vs OCP plus placebo (P)...
March 1, 2018: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29211833/a-prospective-phase-ii-study-of-combined-androgen-blockade-in-patients-with-androgen-receptor-positive-metastatic-or-locally-advanced-unresectable-salivary-gland-carcinoma
#20
C Fushimi, Y Tada, H Takahashi, T Nagao, H Ojiri, T Masubuchi, T Matsuki, K Miura, D Kawakita, H Hirai, E Hoshino, S Kamata, T Saotome
Background: There is no standard first-line chemotherapy for recurrent/metastatic or unresectable locally advanced salivary gland carcinoma (SGC). Patients and methods: We conducted a single institution, open-label, single arm, phase II trial of combined androgen blockade (CAB) for androgen receptor (AR)-positive SGC. Leuprorelin acetate was administered subcutaneously at a dose of 3.75 mg every 4 weeks. Bicalutamide was administered orally at a daily dose of 80 mg...
December 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
keyword
keyword
21362
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"